Reata Pharmaceuticals, Inc. (RETA)

NASDAQ: RETA · IEX Real-Time Price · USD
89.74
+0.36 (0.40%)
At close: Mar 21, 2023, 4:00 PM
89.00
-0.74 (-0.82%)
After-hours: Mar 21, 2023, 7:47 PM EDT
0.4%
Market Cap 3.30B
Revenue (ttm) 2.22M
Net Income (ttm) -311.90M
Shares Out 36.73M
EPS (ttm) -8.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 959,189
Open 89.96
Previous Close 89.38
Day's Range 88.29 - 90.61
52-Week Range 18.47 - 95.00
Beta 1.27
Analysts Buy
Price Target 112.91 (+25.82%)
Earnings Date Mar 27, 2023

About RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 26, 2016
Employees 346
Stock Exchange NASDAQ
Ticker Symbol RETA
Full Company Profile

Financial Performance

In 2022, RETA's revenue was $2.22 million, a decrease of -80.71% compared to the previous year's $11.49 million. Losses were -$311.90 million, 4.88% more than in 2021.

Financial Statements

Analyst Forecast

According to 16 analysts, the average rating for RETA stock is "Buy." The 12-month stock price forecast is $112.91, which is an increase of 25.82% from the latest price.

Price Target
$112.91
(25.82% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Reata (RETA) Stock Doubles This Year on Skyclarys FDA Nod

Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.

1 week ago - Zacks Investment Research

The Stock That Tripled in a Day

Texas-based biotechnology company Reata Pharmaceuticals, Inc. (NASDAQ:RETA) lulled shareholders to sleep in 2022. The news flow was light, the trading pattern sideways and volume virtually nonexistent...

2 weeks ago - MarketBeat

Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel th...

2 weeks ago - Business Wire

The quality of your clinical data drives everything, says Reata Pharma CEO Warren Huff

Warren Huff, CEO of Reata Pharmaceuticals, and CNBC's Meg Tirrell join 'Power Lunch' to discuss Reata's new drug for treating a rare neurological disorder receiving FDA approval.

2 weeks ago - CNBC Television

Reata (RETA) Stock Jumps as FDA Approves Rare Disease Drug

Skyclarys is the first drug to be approved specifically for the treatment of Friedreich's ataxia and is also Reata Pharmaceuticals' (RETA) first commercial product

2 weeks ago - Zacks Investment Research

Cytokinetics will seek international approval for drug following FDA rejection, says CEO Robert Blum

Cytokinetics President and CEO Robert Blum joins 'Power Lunch' to discuss the FDA's rejection of the company's heart failure drug, how FDA approval increases shareholder value and future treatment pla...

Other symbols: CYTK
2 weeks ago - CNBC Television

Reata's stock jumps 175% in premarket trading after FDA approval

Shares of Reata Pharmaceuticals Inc. RETA soared about 175% in premarket trading on Wednesday, the day after the Food and Drug Administration approved Skyclarys, a treatment for Friedreich's ataxia, a...

2 weeks ago - Market Watch

Why Is Reata Pharmaceuticals (RETA) Stock Up 175% Today?

Reata Pharmaceuticals (NASDAQ: RETA) stock is rocketing higher on Wednesday following approval from the FDA for one of its drugs. The FDA approval covers the use of the company's SKYCLARYS as a treat...

2 weeks ago - InvestorPlace

Stocks in focus: Reata Pharmaceuticals stock soars after FDA-drug approval; Novavax falls after vaccine maker issues ‘substantial doubts' over future operations

Here are U.S. stocks in focus ahead of Wednesday's trading session:

Other symbols: NVAX
2 weeks ago - Market Watch

Reata Soars on Approval for Rare Disorder Drug. Its Pipeline Impresses Analysts.

The FDA approves the pharmaceutical company's treatment for Friedreich's ataxia, which Citi analysts expect to generate peak U.S. revenue of around $1.2 billion.

2 weeks ago - Barrons

FDA approves Reata's rare nervous-system drug amid questions about changing regulatory environment for neuroscience treatments

The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.'s treatment for Friedreich's ataxia, a rare inherited disease that causes damage to the nervous system.

3 weeks ago - Market Watch

Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich's Ataxia

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a biopharmaceutical company focused on developing and commercializing novel th...

3 weeks ago - Business Wire

Reata Pharmaceuticals, Inc. (RETA) Soars 6.3%: Is Further Upside Left in the Stock?

Reata Pharmaceuticals, Inc. (RETA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into furthe...

1 month ago - Zacks Investment Research

Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that management will particip...

4 months ago - Business Wire

Reata (RETA) Q3 Earnings Beat, Stock Up on Pipeline Updates

Reata (RETA) reports a narrower-than-expected loss in the third quarter. Stock rises after RETA states that the FDA did not request additional data on the NDA for omaveloxolone in Friedreich's ataxia.

4 months ago - Zacks Investment Research

Reata Pharmaceuticals, Inc. (RETA) Reports Q3 Loss, Lags Revenue Estimates

Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of 8.09% and 62.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for th...

4 months ago - Zacks Investment Research

Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results ...

4 months ago - Business Wire

Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will repor...

5 months ago - Business Wire

Reata Pharmaceuticals Announces Presentations at the International Congress for Ataxia Research 2022

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting cli...

5 months ago - Business Wire

Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing

The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.

5 months ago - Zacks Investment Research

Reata Pharmaceuticals, Inc. (RETA) Stock Jumps 20.6%: Will It Continue to Soar?

Reata Pharmaceuticals, Inc. (RETA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further s...

5 months ago - Zacks Investment Research

Why Is Reata Pharmaceuticals (RETA) Stock Up 15% Today?

On a sharply down day at the tail end of the week, Reata Pharmaceuticals (NASDAQ: RETA) provided a dramatic counterpoint. While the benchmark S&P 500 index slipped near 2% down, RETA stock gained ove...

5 months ago - InvestorPlace

Reata Pharmaceuticals Announces that the FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the NDA for Omaveloxolone for Friedreich's Ataxia

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, announced that the U.S. Food and D...

5 months ago - Business Wire

Reata Pharma (RETA) is Striving Hard Despite Pipeline Setbacks

Reata Pharmaceuticals (RETA) is yet to generate product revenues due to the lack of marketed drugs in its portfolio. However, two of its pipeline candidates are close to potential FDA approval.

6 months ago - Zacks Investment Research

Reata Pharmaceuticals, Inc. (RETA) Up 4.7% Since Last Earnings Report: Can It Continue?

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?

6 months ago - Zacks Investment Research